PL2739153T3 - Leczenie raka sutka - Google Patents

Leczenie raka sutka

Info

Publication number
PL2739153T3
PL2739153T3 PL12846720T PL12846720T PL2739153T3 PL 2739153 T3 PL2739153 T3 PL 2739153T3 PL 12846720 T PL12846720 T PL 12846720T PL 12846720 T PL12846720 T PL 12846720T PL 2739153 T3 PL2739153 T3 PL 2739153T3
Authority
PL
Poland
Prior art keywords
nutc
cancer
treatment
nutc cancer
Prior art date
Application number
PL12846720T
Other languages
English (en)
Inventor
Andrew A. Protter
Jennifer Richer
Dawn Cochrane
Original Assignee
Medivation Prostate Therapeutics Llc
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2739153(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics Llc, Univ Colorado Regents filed Critical Medivation Prostate Therapeutics Llc
Publication of PL2739153T3 publication Critical patent/PL2739153T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12846720T 2011-07-29 2012-07-27 Leczenie raka sutka PL2739153T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer
EP12846720.6A EP2739153B1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (1)

Publication Number Publication Date
PL2739153T3 true PL2739153T3 (pl) 2019-04-30

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12846720T PL2739153T3 (pl) 2011-07-29 2012-07-27 Leczenie raka sutka

Country Status (18)

Country Link
US (4) US9517229B2 (pl)
EP (4) EP3430907A1 (pl)
JP (2) JP6158180B2 (pl)
KR (1) KR101923250B1 (pl)
CN (1) CN103997894B (pl)
BR (1) BR112014002200A2 (pl)
CA (1) CA2843417C (pl)
CY (1) CY1121038T1 (pl)
DK (1) DK2739153T3 (pl)
EA (1) EA028452B1 (pl)
ES (1) ES2696074T3 (pl)
HU (1) HUE040524T2 (pl)
MX (1) MX359664B (pl)
PH (1) PH12014500248B1 (pl)
PL (1) PL2739153T3 (pl)
PT (1) PT2739153T (pl)
SI (1) SI2739153T1 (pl)
WO (1) WO2013066440A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2739153T3 (en) * 2011-07-29 2018-12-03 Medivation Prostate Therapeutics Llc TREATMENT OF BREAST CANCER
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
CA3105575A1 (en) * 2013-01-15 2014-07-24 Aragon Pharmaceuticals, Inc. Androgen receptor modulator and uses thereof
BR112015026257B1 (pt) * 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
CA2929715A1 (en) * 2013-11-07 2015-05-14 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie2 kinase useful in the treatment of cancer
US10238630B2 (en) 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
SG11201704425TA (en) 2014-12-12 2017-06-29 Medivation Prostate Therapeutics Inc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
CN107530291A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 双重负载的脂质体药物制剂
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
UA129105C2 (uk) 2017-10-16 2025-01-15 Арагон Фармасьютикалз, Інк. Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
EA202091763A1 (ru) 2018-01-31 2020-12-14 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Комбинированная терапия для лечения мастоцитоза
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
JP7818502B2 (ja) 2019-08-12 2026-02-20 デシフェラ・ファーマシューティカルズ，エルエルシー 胃腸間質腫瘍を治療するためのリプレチニブ
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
AU2020417282B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
SI4084778T1 (sl) 2019-12-30 2024-01-31 Deciphera Pharmaceuticals, Llc Formulacije inhibitorja amorfne kinaze in načini njihove uporabe
WO2022031630A1 (en) * 2020-08-03 2022-02-10 Oncocyte Corporation Classifying tumors and predicting responsiveness
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP3106162A1 (en) 2005-05-13 2016-12-21 The Regents of the University of California Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US20090299640A1 (en) 2005-11-23 2009-12-03 University Of Utah Research Foundation Methods and Compositions Involving Intrinsic Genes
EP2656842B1 (en) 2006-03-27 2016-08-10 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
WO2007127010A2 (en) * 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
CA2966280A1 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
US8450290B2 (en) * 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
US20110130296A1 (en) * 2008-03-14 2011-06-02 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
AU2009262894B2 (en) 2008-05-30 2014-01-30 British Columbia Cancer Agency Branch Gene expression profiles to predict breast cancer outcomes
MX2011008858A (es) 2009-02-24 2012-01-27 Medivation Prostate Therapeutics Inc Compuestos de diarilhidantoina y diariltiohidantoina especificos.
EP2416657A4 (en) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
US8507195B2 (en) * 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
EP2485804A4 (en) 2009-10-07 2015-07-29 Medivation Technologies Inc SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS
CA2830240A1 (en) 2011-03-15 2012-09-20 The University Of North Carolina At Chapell Hill Methods of treating breast cancer with anthracycline therapy
DK2739153T3 (en) * 2011-07-29 2018-12-03 Medivation Prostate Therapeutics Llc TREATMENT OF BREAST CANCER
CA2857505A1 (en) 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
WO2014031164A1 (en) 2012-08-23 2014-02-27 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US20140154681A1 (en) 2012-11-12 2014-06-05 Nanostring Technologies, Inc. Methods to Predict Breast Cancer Outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
SG11201704425TA (en) 2014-12-12 2017-06-29 Medivation Prostate Therapeutics Inc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

Also Published As

Publication number Publication date
US20170087132A1 (en) 2017-03-30
ES2696074T3 (es) 2019-01-14
CN103997894A (zh) 2014-08-20
HUE040524T2 (hu) 2019-03-28
JP6158180B2 (ja) 2017-07-05
EA201400178A1 (ru) 2014-11-28
EP3791724A1 (en) 2021-03-17
EP2739153A4 (en) 2015-03-11
PH12014500248A1 (en) 2014-03-17
PT2739153T (pt) 2018-11-28
US20140296312A1 (en) 2014-10-02
SI2739153T1 (sl) 2018-12-31
MX2014001218A (es) 2014-08-22
CN103997894B (zh) 2016-08-24
EP2739153A1 (en) 2014-06-11
CA2843417A1 (en) 2013-05-10
CA2843417C (en) 2018-08-21
KR101923250B1 (ko) 2018-11-28
MX359664B (es) 2018-10-05
EA028452B1 (ru) 2017-11-30
HK1201413A1 (en) 2015-09-04
US9517229B2 (en) 2016-12-13
US20190262315A1 (en) 2019-08-29
US10111861B2 (en) 2018-10-30
DK2739153T3 (en) 2018-12-03
CY1121038T1 (el) 2019-12-11
PH12014500248B1 (en) 2018-08-31
US20210069154A1 (en) 2021-03-11
JP2014524934A (ja) 2014-09-25
EP2739153B1 (en) 2018-08-22
WO2013066440A9 (en) 2013-07-18
EP3430907A1 (en) 2019-01-23
WO2013066440A1 (en) 2013-05-10
EP3610731A1 (en) 2020-02-19
JP2017141269A (ja) 2017-08-17
BR112014002200A2 (pt) 2017-03-07
HK1198867A1 (en) 2015-06-19
KR20140107174A (ko) 2014-09-04

Similar Documents

Publication Publication Date Title
IL289300A (en) Combination therapy for treating cancer
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2739153T3 (pl) Leczenie raka sutka
IL262956B (en) Methods for increasing efficacy of folr1 cancer therapy
DK2717941T3 (da) Behandling af cancer
HUE046790T2 (hu) A rák kezelésének módszerei
BR112014007603A2 (pt) métodos de tratamento do câncer
HUE047198T2 (hu) Fitokannabinoidok emlõrák kezelésére
DK2785349T4 (da) Kombinationsbehandling af cancer
LT2885010T (lt) Tautopatijos gydymo būdai
PL2552438T3 (pl) Sposoby leczenia raka wątrobowokomórkowego
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
EP2920308A4 (en) CANCER TREATMENT
BR112014012880A2 (pt) tratamento imunogênico do câncer
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
IL226246A0 (en) Methods of treating cancer
IL228430A0 (en) Cancer treatment
EP2817011A4 (en) CANCER TREATMENT
EP2903644A4 (en) TREATMENT OF CANCER
GB201217892D0 (en) Treatment of cancer
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
PL2780003T3 (pl) Leczenie niedoczynności kory nadnerczy
DK2694056T3 (da) Terapeutisk behandling
GB201217890D0 (en) Treatment of cancer
GB201121783D0 (en) Treatment of cancer